Ozempic Offers Heart Protection Beyond Weight Loss, Groundbreaking Study Reveals Surprising Cardiovascular Benefits

Ozempic Offers Heart Protection Beyond Weight Loss, Groundbreaking Study Reveals Surprising Cardiovascular Benefits

Recent research has revealed that the heart health benefits of the weight loss drug Ozempic, which contains the active ingredient semaglutide, are not solely due to weight loss. A large study published in The Lancet and led by researchers at University College London analyzed data from more than seventeen thousand adults aged forty five and older who were overweight and had cardiovascular disease. The participants were randomly assigned to receive weekly injections of semaglutide or a placebo. The study found that semaglutide significantly reduced the risk of major cardiac events such as heart attacks, strokes, and cardiovascular deaths, regardless of how much weight each participant lost during the first four and a half months of treatment. This means that even people who lost little or no weight experienced similar heart protection as those who lost a substantial amount.

The study also looked at the impact of waist circumference, which is a marker for visceral fat, and found that a reduction in waist size was linked to about one third of the heart benefits seen in patients taking semaglutide. However, the majority of the cardiovascular benefit was not explained by changes in weight or waist size alone. This suggests that semaglutide may have direct effects on the underlying causes of heart disease, beyond just helping people lose weight. Experts say this could mean the drug might be beneficial for patients who are not severely overweight, including those with BMIs in the normal range, although further research is needed to confirm this.

Oprah Winfrey has recently spoken about her own experience with Ozempic, describing it as a tool she uses to manage her weight. She has emphasized that medication is not the only way to lose weight and that it should be seen as one option among many. Oprah has also discussed the broader cultural conversation around weight loss drugs, highlighting the need to address weight stigma and body shaming. Her openness has sparked a national dialogue about the role of prescription medications in weight management and the importance of focusing on overall health rather than just appearance.

The findings from the latest research are prompting doctors and researchers to reconsider how they approach the treatment of obesity and heart disease. While Ozempic and similar drugs were originally developed for diabetes, their ability to protect the heart even without significant weight loss is a major development. This could lead to new treatment strategies for people at high risk of cardiovascular events, regardless of their body size. As the medical community continues to explore the full range of benefits and risks associated with these medications, the conversation around weight loss and heart health is becoming more nuanced and inclusive.

Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

Avsnitt(74)

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

GLP-1 Weight Loss Drugs Ozempic and Mounjaro Show 11 to 16 Percent Results Despite Side Effects

Recent Cochrane reviews commissioned by the World Health Organization show that blockbuster weight loss drugs like Ozempic deliver substantial results. According to ScienceDaily reporting on February ...

18 Feb 2min

GLP-1 Weight Loss Drugs Show Promise: Semaglutide and Tirzepatide Lead Clinical Reviews in 2026

GLP-1 Weight Loss Drugs Show Promise: Semaglutide and Tirzepatide Lead Clinical Reviews in 2026

Recent news highlights ongoing developments in weight loss treatments like Ozempic, with fresh insights from clinical reviews and patient experiences. On February 11, 2026, Cochrane reviews commission...

14 Feb 3min

Ozempic and Wegovy Weight Loss: Benefits, Risks, and Expert Nutrition Guidance

Ozempic and Wegovy Weight Loss: Benefits, Risks, and Expert Nutrition Guidance

Recent research from the University of Cambridge highlights a key concern with popular weight-loss drugs like Ozempic and Wegovy. These medications sharply reduce appetite, leading to calorie intake d...

11 Feb 2min

GLP-1 Drugs Like Ozempic Transform Weight Loss Landscape in 2026 With Major Health and Industry Implications

GLP-1 Drugs Like Ozempic Transform Weight Loss Landscape in 2026 With Major Health and Industry Implications

In the past week, weight loss drugs like Ozempic, Wegovy, and Mounjaro have reshaped global conversations on obesity, marking 2026 as a potential turning point. Firstpost reports that these GLP-1 drug...

7 Feb 2min

Novo Nordisk CagriSema Outperforms Ozempic in Phase III Trial for Type 2 Diabetes and Weight Loss

Novo Nordisk CagriSema Outperforms Ozempic in Phase III Trial for Type 2 Diabetes and Weight Loss

Novo Nordisk's new drug CagriSema has outperformed Ozempic in a recent Phase III trial for type 2 diabetes patients, according to Clinical Trials Arena. In the REIMAGINE 2 study, CagriSema reduced HbA...

4 Feb 2min

Oprah Endorses GLP-1 Drugs for Weight Loss as Regulators Issue New Safety Guidance on Semaglutide

Oprah Endorses GLP-1 Drugs for Weight Loss as Regulators Issue New Safety Guidance on Semaglutide

Oprah Winfrey has been candid this week about her ongoing use of GLP-1 medications like those containing semaglutide, the active ingredient in Ozempic, for weight management. In recent interviews prom...

31 Jan 2min

GLP-1 Medications Transform Weight Loss Treatment as Medicaid Coverage Remains Inconsistent Across States

GLP-1 Medications Transform Weight Loss Treatment as Medicaid Coverage Remains Inconsistent Across States

The landscape of weight loss treatment in America is shifting dramatically as glucagon-like peptide-one receptor agonists, or GLP-1s, continue to dominate conversations about obesity management. Accor...

28 Jan 2min

Oprah Reveals Ozempic Weight Regain After Stopping Drug, Experts Warn of Lifelong Dependency

Oprah Reveals Ozempic Weight Regain After Stopping Drug, Experts Warn of Lifelong Dependency

Oprah Winfrey shared striking insights this week on her experience with Ozempic, a popular drug known as semaglutide for type two diabetes and weight management. On the Today Show on January 21, 2026,...

24 Jan 2min

Populärt inom Politik & nyheter

svenska-fall
aftonbladet-krim
p3-krim
rss-krimstad
blenda-2
flashback-forever
politiken
rss-vad-fan-hande
rss-krimreportrarna
rss-sanning-konsekvens
aftonbladet-daily
motiv
spar
grans
rss-frandfors-horna
svd-ledarredaktionen
rss-flodet
dagens-eko
olyckan-inifran
krimmagasinet